Deals - Diagnostic Devices

Francis Medical completes $18m round of Series A financing

Francis Medical, a company engaged in the development of developing urological cancer treatments, has raised $18m Series A funding for cancer ablation technology using water vapor.

LGC acquires SeraCare Life Sciences

LGC, which owned by funds affiliated with global investment firm KKR. has acquired SeraCare Life Sciences to strengthen its position in clinical quality control tools.

Boston Scientific offers to acquire BTG for $4.2bn

Boston Scientific, an American manufacturer of medical devices used in interventional medical specialties, has announced a recommended offer to acquire the UK-based healthcare firm BTG for $4.2bn.

Illumina to acquire Pacific Biosciences for $1.2bn

Illumina, a sequencing and array-based solutions provider for genetic research, has agreed to acquire sequencing systems provider Pacific Biosciences for $1.2bn in an all-cash transaction.

GTCR acquires Medelec and STI Laser Industries

Private equity firm GTCR has acquired Medelec and STI Laser Industries to transform Resonetics into global platform.

Strand Life Sciences to buy Quest’s Indian diagnostics business

Diagnostic information services provider Quest Diagnostics has entered into an agreement to divest its medical diagnostics business in India to Strand Life Sciences for an undisclosed sum.

ivWatch signs deal with ICU Medical to provide customers interoperability

ivWatch, a provider of continuous monitoring devices for the early identification of intravenous (IV) infiltrations and extravasations, has signed a long-term development and commercialization agreement with ICU Medical.

AngioDynamics to buy medical diagnostic and device firm RadiaDyne

AngioDynamics has signed an agreement to acquire medical diagnostic and device firm, RadiaDyne, for an undisclosed sum.

Boston Scientific to buy prostate therapy developer Augmenix in $600m deal

Medical technology firm Boston Scientific has agreed to acquire US-based prostate therapy developer Augmenix in an agreement valued at around $600m.